John Papandrea, MD
Internal Medicine · West Hartford, CTNPI 1083638837
Payments from drug & device makers
Across 356 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$761
- Pfizer$577
- Boehringer Ingelheim$453
- GSK$437
- Lilly USA, LLC$391
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,90999%
- Education$921%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 66 | $1,150 |
| AbbVie(2 entities) | 39 | $761 |
| Pfizer | 33 | $577 |
| Boehringer Ingelheim | 19 | $453 |
| GSK | 21 | $437 |
| Lilly USA, LLC | 20 | $391 |
| Sanofi-aventis U.S. LLC | 16 | $329 |
| Johnson & Johnson | 19 | $313 |
| Abbott | 13 | $291 |
| AstraZeneca | 12 | $229 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $212 |
| Merck | 13 | $207 |
| Bayer | 8 | $205 |
| E.r. Squibb & Sons, L.L.C. | 9 | $178 |
| Exact Sciences | 6 | $141 |
| Astellas Pharma US Inc | 5 | $118 |
| Novartis | 5 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $104 |
| Kowa Pharmaceuticals America, Inc. | 5 | $83 |
| Amgen(2 entities) | 5 | $81 |
| Sumitomo Pharma America, Inc. | 3 | $71 |
| Lundbeck LLC | 3 | $70 |
| Phathom Pharmaceuticals, Inc. | 3 | $68 |
| Otsuka America Pharmaceutical, Inc. | 3 | $60 |
| Teleflex LLC | 1 | $55 |
| Dexcom, Inc. | 2 | $46 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Medtronic | 1 | $27 |
| Axonics, Inc. | 1 | $27 |
| Almatica Pharma LLC | 1 | $26 |
| Shire North American Group Inc | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Assertio Therapeutics, Inc. | 1 | $19 |
| Bausch Health US, LLC | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Vistapharm, Inc. | 1 | $15 |
How this compares
$7,001 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 92 | $149,425 |
| EliquisApixaban | 89 | $90,791 |
| OzempicSemaglutide | 58 | $88,033 |
| XareltoRivaroxaban | 43 | $59,287 |
| JanuviaSitagliptin Phosphate | 48 | $57,163 |
| JanumetSitagliptin Phos/Metformin Hcl | 33 | $53,579 |
| FarxigaDapagliflozin Propanediol | 31 | $49,357 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $20,145 |
| Lubiprostone | 23 | $8,263 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,448 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $6,840 |
| Wixela InhubFluticasone Propion/Salmeterol | 63 | $6,162 |
| Rosuvastatin Calcium | 459 | $5,211 |
| Levemir FlexpenInsulin Detemir | 22 | $4,388 |
| Atorvastatin Calcium | 561 | $4,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $453 | $149,42592 claims |
| MerckJanuvia, Janumet, Janumet Xr | $207 | $130,88795 claims |
| PfizerEliquis, Premarin, Paxlovid | $577 | $96,266127 claims |
| Novo NordiskOzempic | $1,150 | $88,03358 claims |
| Johnson & JohnsonXarelto | $313 | $59,28743 claims |
| AstraZenecaFarxiga | $229 | $49,35731 claims |
| AbbVieSynthroid | $761 | $2,58619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.
Other internal medicine in West Hartford
- Murray WellnerWest Hartford$63K
- Julian ParsonsWest Hartford$36K
- Joseph SouferWaterbury$21.5M
- David RadinStamford$7M
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$2.8M
- Charles MontanoCromwell$2.8M
- Arthur DecillisMadison$1M
- Michelle MallitzTrumbull$971K
- Allen HellerWoodbridge$758K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.